Interventional Glaucoma

First-in-human feasibility study.

AMDX-2011P aims to revolutionize glaucoma detection with micron-level amyloid beta tracking.

Ab-interno implantation of a supraciliary allograft bio-tissue successfully reduced intraocular pressure (IOP) with comparable safety to other minimally invasive glaucoma surgical (MIGS) procedures

Eight patients were able to receive a second implant at 21 weeks, with no product related adverse effects.

According to the company, its Phase I/II trial is being initiated to investigate SpyGlass platform for the long-term delivery of bimatoprost in patients with glaucoma and visually significant cataracts.

According to the company, its ViaLase Laser combines the precision of femtosecond laser technology and the accuracy of micron-level image guidance to deliver the world's first femtosecond laser image-guided high-precision trabeculotomy.

According to Stuart, the agreement will grant Glaukos exclusive worldwide rights to develop and commercialize the company’s ST-113 drug candidate for neuroprotection in glaucoma.

Thomas V. Johnson, MD, PhD, notes the value of home monitoring lies in its ability to provide real-time insights into IOP fluctuations, enabling more precise glaucoma care and a deeper understanding of the patient's risk for vision loss.

Glaucoma specialist Joel Solano, MD, connects patients diagnosed with glaucoma with digital health solutions that can help prevent blindness and vision loss.

Preservative-free Iyuzeh, launched more than 10 years ago, currently is available in 46 countries, mostly under the brand name Monoprost, with about 1.5 million patients treated monthly, according to the company.

Highlighting the benefits of Iridex's updated P3 Probe and Cyclo G6® Laser software for MicroPulse® transscleral laser therapy. The redesigned probe improves ergonomics and visibility, while the user-friendly software ensures precise, reproducible glaucoma treatments.

As a gold medalist with profound vision loss, she will lead advocacy efforts for people with glaucoma that are designed to empower patients to participate actively in their glaucoma treatment journey

Leaders must confront issues perpetuating unequal access, unfair practices.

MERCURY-3 trial data show latanoprost/netarsudil fixed-dose combination (Roclanda) demonstrated comparable IOP lowering efficacy to bimatoprost/timolol combination, in patients with primary open-angle glaucoma or ocular hypertension.

Patients with HTG had significantly fewer mtDNA copies per nuclear DNA.

According researchers at the University of Gothenburg, for patients who recently received a diagnosis, discovery of glaucoma could mean they start treatment with daily eye drops that lower the pressure in the eye and slow down the damage to the optic nerve.

The trial is for the MINIject MIGS device for patients with primary open-angle glaucoma.

The system is a next generation aqueous shunt therapy for patients with moderate to severe glaucoma.

Brimonidine is an alpha-adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

TRS01 demonstrates clear anti-inflammatory activity in noninfectious anterior uveitis with no evidence of significant adverse effects.

Oluwatosin U. Smith, MD, shares why she is excited for the conference and why it is relevant for today’s ophthalmologists and optometrists.

Santen will receive an equity stake in Visiox as an upfront payment, and remains eligible to receive sales milestone payments, as well as royalties on net sales of omidenepag isopropyl ophthalmic solution in the United States.

According to the company, the financing will advance novel treatments for glaucoma and other chronic ophthalmic diseases by supporting multiple US clinical trials of its drug delivery platform.

The second issue of the 2023 Video Journal of Cataract, Refractive, & Glaucoma Surgery offers a compilation of 27 surgical highlights from the ESCRS meeting in Milan, providing valuable education for global anterior segment surgeons.

The company announced its contract manufacture, NextPharma, completed filling of the drug materials into strips of 10 single-use vials for use in upcoming glaucoma trial.

Procedures in the pipeline hold greater appeal for cataract and refractive surgeons, patients.

The company seeks to replicate European success of the ELIOS procedure in the US market.

The funds will be used to further develop the company’s Calibreye System that aims to optimize reduction of intraocular pressure (IOP) for patients with moderate to advanced glaucoma.

According to researchers, the study is the first to assess associations between pre-diagnostic circulating metabolites and POAG risk in two large independent datasets.

Cigna’s Coverage Policy includes procedures enabled with OMNI® Surgical System technology as medically necessary and covered.